Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Terminated · Phase 1 · NCT02200848
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
At a glance
- Research payments reported, 2025
- $166,908
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 5
About the trial
- Sponsor
- Georgetown University (with National Cancer Institute (NCI))
- Tested
- Lenalidomide, Ibrutinib, Rituximab (drug)
- Dates
- Started 2014-04; completion 2017-08-01
- Results posted
- Not yet
This study is for subjects diagnosed with recurrent or relapsed CLL/SLL. The purpose of this study is to test the safety of the combination of the drugs lenalidomide and ibrutinib at different dose levels, in combination with the drug rituximab. We want to find out what effects, good and/or bad, they have on patients with CLL/SLL. The hypothesis of the study is that it will be safe to give the three drugs in combination and the information learned from this trial will be used to study the 3 drug combination is a larger future trial.
From ClinicalTrials.gov, last updated 2018-01-12. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $166,908 in research payments for this study in 2025 (3 payments).
Products named: Imbruvica
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- National Institute of Health $166,908
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.